Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

Efflux pump-mediated drug resistance in Burkholderia.

Podnecky NL, Rhodes KA, Schweizer HP.

Front Microbiol. 2015 Apr 14;6:305. doi: 10.3389/fmicb.2015.00305. eCollection 2015.

2.

A Burkholderia pseudomallei colony variant necessary for gastric colonization.

Austin CR, Goodyear AW, Bartek IL, Stewart A, Sutherland MD, Silva EB, Zweifel A, Vitko NP, Tuanyok A, Highnam G, Mittelman D, Keim P, Schweizer HP, Vázquez-Torres A, Dow SW, Voskuil MI.

MBio. 2015 Feb 3;6(1). pii: e02462-14. doi: 10.1128/mBio.02462-14.

3.

Tn5/7-lux: a versatile tool for the identification and capture of promoters in gram-negative bacteria.

Bruckbauer ST, Kvitko BH, Karkhoff-Schweizer RR, Schweizer HP.

BMC Microbiol. 2015 Feb 4;15:17. doi: 10.1186/s12866-015-0354-3.

4.

Blocking phosphatidylcholine utilization in Pseudomonas aeruginosa, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source in vivo.

Sun Z, Kang Y, Norris MH, Troyer RM, Son MS, Schweizer HP, Dow SW, Hoang TT.

PLoS One. 2014 Jul 28;9(7):e103778. doi: 10.1371/journal.pone.0103778. eCollection 2014.

5.

Rapid Burkholderia pseudomallei identification and antibiotic resistance determination by bacteriophage amplification and MALDI-TOF MS.

Cox CR, Saichek NR, Schweizer HP, Voorhees KJ.

Bacteriophage. 2014 Apr 25;4:e29011. eCollection 2014.

6.

New insights from the 7th World Melioidosis Congress 2013.

Schweizer HP, Limmathurotsakul D, Peacock SJ.

Emerg Infect Dis. 2014 Jul;20(7). doi: 10.3201/eid2007.131737. No abstract available.

7.

Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei.

Cummings JE, Beaupre AJ, Knudson SE, Liu N, Yu W, Neckles C, Wang H, Khanna A, Bommineni GR, Trunck LA, Schweizer HP, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2014;58(3):1646-51. doi: 10.1128/AAC.02296-13. Epub 2013 Dec 30.

8.

The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.

Cummings JE, Kingry LC, Rholl DA, Schweizer HP, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2014;58(2):931-5. doi: 10.1128/AAC.00176-13. Epub 2013 Nov 25.

9.

Polar lipids of Burkholderia pseudomallei induce different host immune responses.

Gonzalez-Juarrero M, Mima N, Trunck LA, Schweizer HP, Bowen RA, Dascher K, Mwangi W, Eckstein TM.

PLoS One. 2013 Nov 18;8(11):e80368. doi: 10.1371/journal.pone.0080368. eCollection 2013.

10.

Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Silva EB, Goodyear A, Sutherland MD, Podnecky NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW.

Infect Immun. 2013 Dec;81(12):4626-34. doi: 10.1128/IAI.00915-13. Epub 2013 Oct 7.

11.

An improved selective culture medium enhances the isolation of Burkholderia pseudomallei from contaminated specimens.

Goodyear A, Strange L, Rholl DA, Silisouk J, Dance DA, Schweizer HP, Dow S.

Am J Trop Med Hyg. 2013 Nov;89(5):973-82. doi: 10.4269/ajtmh.13-0119. Epub 2013 Sep 23.

12.

High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an opp oligopeptide permease encoded by the opp-fabI operon.

Mistry A, Warren MS, Cusick JK, Karkhoff-Schweizer RR, Lomovskaya O, Schweizer HP.

Antimicrob Agents Chemother. 2013 Nov;57(11):5565-71. doi: 10.1128/AAC.01198-13. Epub 2013 Aug 26.

13.

The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates.

Podnecky NL, Wuthiekanun V, Peacock SJ, Schweizer HP.

Antimicrob Agents Chemother. 2013 Sep;57(9):4381-6. doi: 10.1128/AAC.00660-13. Epub 2013 Jul 1.

14.

Does microbicide use in consumer products promote antimicrobial resistance? A critical review and recommendations for a cohesive approach to risk assessment.

Maillard JY, Bloomfield S, Coelho JR, Collier P, Cookson B, Fanning S, Hill A, Hartemann P, McBain AJ, Oggioni M, Sattar S, Schweizer HP, Threlfall J.

Microb Drug Resist. 2013 Oct;19(5):344-54. doi: 10.1089/mdr.2013.0039. Epub 2013 Jun 14. Review.

PMID:
23768140
15.

An improved method for oriT-directed cloning and functionalization of large bacterial genomic regions.

Kvitko BH, McMillan IA, Schweizer HP.

Appl Environ Microbiol. 2013 Aug;79(16):4869-78. doi: 10.1128/AEM.00994-13. Epub 2013 Jun 7.

16.

Construction of mobilizable mini-Tn7 vectors for bioluminescent detection of gram-negative bacteria and single-copy promoter lux reporter analysis.

Damron FH, McKenney ES, Barbier M, Liechti GW, Schweizer HP, Goldberg JB.

Appl Environ Microbiol. 2013 Jul;79(13):4149-53. doi: 10.1128/AEM.00640-13. Epub 2013 Apr 12.

17.

Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.

Schweizer HP.

Future Microbiol. 2012 Dec;7(12):1389-99. doi: 10.2217/fmb.12.116. Review.

18.

φX216, a P2-like bacteriophage with broad Burkholderia pseudomallei and B. mallei strain infectivity.

Kvitko BH, Cox CR, DeShazer D, Johnson SL, Voorhees KJ, Schweizer HP.

BMC Microbiol. 2012 Dec 7;12:289. doi: 10.1186/1471-2180-12-289.

19.

Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.

Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, Currie BJ, Dance D, Gee JE, Larsen J, Limmathurotsakul D, Morrow MG, Norton R, O'Mara E, Peacock SJ, Pesik N, Rogers LP, Schweizer HP, Steinmetz I, Tan G, Tan P, Wiersinga WJ, Wuthiekanun V, Smith TL.

Emerg Infect Dis. 2012 Dec;18(12):e2. doi: 10.3201/eid1812.120638.

20.

Construction of a broad-host-range Tn7-based vector for single-copy P(BAD)-controlled gene expression in gram-negative bacteria.

Damron FH, McKenney ES, Schweizer HP, Goldberg JB.

Appl Environ Microbiol. 2013 Jan;79(2):718-21. doi: 10.1128/AEM.02926-12. Epub 2012 Nov 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk